Pfizer Net Worth
Pfizer Net Worth Breakdown | PFE |
Pfizer Net Worth Analysis
Pfizer's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pfizer's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pfizer's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pfizer's net worth analysis. One common approach is to calculate Pfizer's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pfizer's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pfizer's net worth. This approach calculates the present value of Pfizer's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pfizer's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pfizer's net worth. This involves comparing Pfizer's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pfizer's net worth relative to its peers.
Enterprise Value |
|
To determine if Pfizer is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pfizer's net worth research are outlined below:
| Pfizer Inc generated a negative expected return over the last 90 days | |
| About 67.0% of the company shares are owned by institutional investors | |
| On 7th of March 2025 Pfizer paid $ 0.43 per share dividend to its current shareholders | |
| Latest headline from aol.com: Are COVID-19 Vaccines Safe and Effective |
Pfizer Quarterly Good Will |
|
Pfizer uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pfizer Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pfizer's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of May 2024 Upcoming Quarterly Report | View | |
| 6th of August 2024 Next Financial Report | View | |
| 31st of March 2024 Next Fiscal Quarter End | View | |
| 4th of February 2025 Next Fiscal Year End | View | |
| 31st of December 2023 Last Quarter Report | View | |
| 31st of December 2023 Last Financial Announcement | View |
Pfizer Target Price Consensus
Pfizer target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Pfizer's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 25 | Buy |
Most Pfizer analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Pfizer stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Pfizer Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPfizer Target Price Projection
Pfizer's current and average target prices are 26.05 and 31.78, respectively. The current price of Pfizer is the price at which Pfizer Inc is currently trading. On the other hand, Pfizer's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Pfizer Target Price
Know Pfizer's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pfizer is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pfizer Inc backward and forwards among themselves. Pfizer's institutional investor refers to the entity that pools money to purchase Pfizer's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 45.1 M | Capital World Investors | 2024-12-31 | 43.6 M | Bank Of New York Mellon Corp | 2024-12-31 | 39.9 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 39.4 M | Legal & General Group Plc | 2024-12-31 | 36.9 M | Amundi | 2024-12-31 | 36.3 M | Royal Bank Of Canada | 2024-12-31 | 33.5 M | Amvescap Plc. | 2024-12-31 | 29.5 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 29.3 M | Vanguard Group Inc | 2024-12-31 | 518.5 M | Blackrock Inc | 2024-12-31 | 451.7 M |
Follow Pfizer's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 145.87 B.Market Cap |
|
Project Pfizer's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.11 | |
| Return On Capital Employed | 0.09 | 0.08 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.09 | 0.09 |
When accessing Pfizer's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pfizer's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pfizer's profitability and make more informed investment decisions.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Evaluate Pfizer's management efficiency
Pfizer Inc has Return on Asset of 0.0464 % which means that on every $100 spent on assets, it made $0.0464 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0906 %, implying that it generated $0.0906 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.11, whereas Return On Capital Employed is forecasted to decline to 0.08. At present, Pfizer's Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 107.5 B, whereas Non Currrent Assets Other are forecasted to decline to about 5.5 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 15.62 | 16.41 | |
| Tangible Book Value Per Share | (6.26) | (5.94) | |
| Enterprise Value Over EBITDA | 11.74 | 15.55 | |
| Price Book Value Ratio | 1.70 | 1.62 | |
| Enterprise Value Multiple | 11.74 | 15.55 | |
| Price Fair Value | 1.70 | 1.62 | |
| Enterprise Value | 83.2 B | 87.3 B |
The strategic decisions made by Pfizer management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Enterprise Value Revenue 2.9711 | Revenue | Quarterly Revenue Growth 0.219 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pfizer insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Boshoff Christoffel over a month ago Disposition of 12038 shares by Boshoff Christoffel of Pfizer at 26.52 subject to Rule 16b-3 | ||
John Young over a year ago Acquisition by John Young of tradable shares of Pfizer subject to Rule 16b-3 |
Pfizer Corporate Filings
| 13th of March 2025 Other Reports | ViewVerify | |
F4 | 6th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of March 2025 Other Reports | ViewVerify | |
| 27th of February 2025 Other Reports | ViewVerify |
Pfizer Earnings Estimation Breakdown
The calculation of Pfizer's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pfizer is estimated to be 0.7133 with the future projection ranging from a low of 0.54 to a high of 0.81. Please be aware that this consensus of annual earnings estimates for Pfizer Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.54 Lowest | Expected EPS | 0.81 Highest |
Pfizer Earnings Projection Consensus
Suppose the current estimates of Pfizer's value are higher than the current market price of the Pfizer stock. In this case, investors may conclude that Pfizer is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pfizer's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 23 | 68.05% | 0.63 | 0.7133 | 1.41 |
Pfizer Earnings History
Earnings estimate consensus by Pfizer Inc analysts from Wall Street is used by the market to judge Pfizer's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Pfizer's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Pfizer Quarterly Gross Profit |
|
Pfizer Earnings per Share Projection vs Actual
Actual Earning per Share of Pfizer refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pfizer Inc predict the company's earnings will be in the future. The higher the earnings per share of Pfizer, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Pfizer Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Pfizer, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pfizer should always be considered in relation to other companies to make a more educated investment decision.Pfizer Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Pfizer's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-04 | 2024-12-31 | 0.49 | 0.63 | 0.14 | 28 | ||
2024-10-29 | 2024-09-30 | 0.62 | 1.06 | 0.44 | 70 | ||
2024-07-30 | 2024-06-30 | 0.46 | 0.6 | 0.14 | 30 | ||
2024-05-01 | 2024-03-31 | 0.52 | 0.82 | 0.3 | 57 | ||
2024-01-30 | 2023-12-31 | -0.22 | 0.1 | 0.32 | 145 | ||
2023-10-31 | 2023-09-30 | -0.34 | -0.17 | 0.17 | 50 | ||
2023-08-01 | 2023-06-30 | 0.57 | 0.67 | 0.1 | 17 | ||
2023-05-02 | 2023-03-31 | 0.98 | 1.23 | 0.25 | 25 | ||
2023-01-31 | 2022-12-31 | 1.05 | 1.14 | 0.09 | 8 | ||
2022-11-01 | 2022-09-30 | 1.39 | 1.78 | 0.39 | 28 | ||
2022-07-28 | 2022-06-30 | 1.78 | 2.04 | 0.26 | 14 | ||
2022-05-03 | 2022-03-31 | 1.47 | 1.67 | 0.2 | 13 | ||
2022-02-08 | 2021-12-31 | 0.87 | 1.08 | 0.21 | 24 | ||
2021-11-02 | 2021-09-30 | 1.09 | 1.34 | 0.25 | 22 | ||
2021-07-28 | 2021-06-30 | 0.97 | 1.07 | 0.1 | 10 | ||
2021-05-04 | 2021-03-31 | 0.77 | 0.93 | 0.16 | 20 | ||
2021-02-02 | 2020-12-31 | 0.48 | 0.42 | -0.06 | 12 | ||
2020-10-27 | 2020-09-30 | 0.71 | 0.72 | 0.01 | 1 | ||
2020-07-28 | 2020-06-30 | 0.66 | 0.78 | 0.12 | 18 | ||
2020-04-28 | 2020-03-31 | 0.73 | 0.8 | 0.07 | 9 | ||
2020-01-28 | 2019-12-31 | 0.58 | 0.55 | -0.03 | 5 | ||
2019-10-29 | 2019-09-30 | 0.62 | 0.75 | 0.13 | 20 | ||
2019-07-29 | 2019-06-30 | 0.75 | 0.8 | 0.05 | 6 | ||
2019-04-30 | 2019-03-31 | 0.75 | 0.85 | 0.1 | 13 | ||
2019-01-29 | 2018-12-31 | 0.63 | 0.64 | 0.01 | 1 | ||
2018-10-30 | 2018-09-30 | 0.75 | 0.78 | 0.03 | 4 | ||
2018-07-31 | 2018-06-30 | 0.74 | 0.81 | 0.07 | 9 | ||
2018-05-01 | 2018-03-31 | 0.74 | 0.77 | 0.03 | 4 | ||
2018-01-30 | 2017-12-31 | 0.56 | 0.62 | 0.06 | 10 | ||
2017-10-31 | 2017-09-30 | 0.64 | 0.67 | 0.03 | 4 | ||
2017-08-01 | 2017-06-30 | 0.66 | 0.67 | 0.01 | 1 | ||
2017-05-02 | 2017-03-31 | 0.67 | 0.69 | 0.02 | 2 | ||
2017-01-31 | 2016-12-31 | 0.5 | 0.47 | -0.03 | 6 | ||
2016-11-01 | 2016-09-30 | 0.62 | 0.61 | -0.01 | 1 | ||
2016-08-02 | 2016-06-30 | 0.62 | 0.64 | 0.02 | 3 | ||
2016-05-03 | 2016-03-31 | 0.55 | 0.67 | 0.12 | 21 | ||
2016-02-02 | 2015-12-31 | 0.52 | 0.53 | 0.01 | 1 | ||
2015-10-27 | 2015-09-30 | 0.51 | 0.6 | 0.09 | 17 | ||
2015-07-28 | 2015-06-30 | 0.52 | 0.56 | 0.04 | 7 | ||
2015-04-28 | 2015-03-31 | 0.49 | 0.51 | 0.02 | 4 | ||
2015-01-27 | 2014-12-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2014-10-28 | 2014-09-30 | 0.55 | 0.57 | 0.02 | 3 | ||
2014-07-29 | 2014-06-30 | 0.57 | 0.58 | 0.01 | 1 | ||
2014-05-05 | 2014-03-31 | 0.55 | 0.57 | 0.02 | 3 | ||
2014-01-28 | 2013-12-31 | 0.52 | 0.56 | 0.04 | 7 | ||
2013-10-29 | 2013-09-30 | 0.56 | 0.58 | 0.02 | 3 | ||
2013-07-30 | 2013-06-30 | 0.55 | 0.56 | 0.01 | 1 | ||
2013-04-30 | 2013-03-31 | 0.55 | 0.54 | -0.01 | 1 | ||
2013-01-29 | 2012-12-31 | 0.44 | 0.47 | 0.03 | 6 | ||
2012-11-01 | 2012-09-30 | 0.53 | 0.53 | 0.0 | 0 | ||
2012-07-31 | 2012-06-30 | 0.54 | 0.62 | 0.08 | 14 | ||
2012-05-01 | 2012-03-31 | 0.56 | 0.58 | 0.02 | 3 | ||
2012-01-31 | 2011-12-31 | 0.47 | 0.5 | 0.03 | 6 | ||
2011-11-01 | 2011-09-30 | 0.56 | 0.62 | 0.06 | 10 | ||
2011-08-02 | 2011-06-30 | 0.59 | 0.6 | 0.01 | 1 | ||
2011-05-03 | 2011-03-31 | 0.59 | 0.6 | 0.01 | 1 | ||
2011-02-01 | 2010-12-31 | 0.46 | 0.47 | 0.01 | 2 | ||
2010-11-02 | 2010-09-30 | 0.51 | 0.54 | 0.03 | 5 | ||
2010-08-03 | 2010-06-30 | 0.52 | 0.62 | 0.1 | 19 | ||
2010-05-04 | 2010-03-31 | 0.53 | 0.6 | 0.07 | 13 | ||
2010-02-03 | 2009-12-31 | 0.5 | 0.49 | -0.01 | 2 | ||
2009-10-20 | 2009-09-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2009-07-22 | 2009-06-30 | 0.47 | 0.48 | 0.01 | 2 | ||
2009-04-28 | 2009-03-31 | 0.49 | 0.54 | 0.05 | 10 | ||
2009-01-26 | 2008-12-31 | 0.59 | 0.65 | 0.06 | 10 | ||
2008-10-21 | 2008-09-30 | 0.6 | 0.62 | 0.02 | 3 | ||
2008-07-23 | 2008-06-30 | 0.54 | 0.55 | 0.01 | 1 | ||
2008-04-17 | 2008-03-31 | 0.66 | 0.61 | -0.05 | 7 | ||
2008-01-23 | 2007-12-31 | 0.47 | 0.52 | 0.05 | 10 | ||
2007-10-18 | 2007-09-30 | 0.53 | 0.58 | 0.05 | 9 | ||
2007-07-18 | 2007-06-30 | 0.5 | 0.42 | -0.08 | 16 | ||
2007-04-20 | 2007-03-31 | 0.57 | 0.68 | 0.11 | 19 | ||
2007-01-22 | 2006-12-31 | 0.42 | 0.43 | 0.01 | 2 | ||
2006-10-19 | 2006-09-30 | 0.45 | 0.54 | 0.09 | 20 | ||
2006-07-20 | 2006-06-30 | 0.48 | 0.5 | 0.02 | 4 | ||
2006-04-19 | 2006-03-31 | 0.53 | 0.61 | 0.08 | 15 | ||
2006-01-19 | 2005-12-31 | 0.42 | 0.51 | 0.09 | 21 | ||
2005-10-20 | 2005-09-30 | 0.48 | 0.51 | 0.03 | 6 | ||
2005-07-20 | 2005-06-30 | 0.44 | 0.46 | 0.02 | 4 | ||
2005-04-19 | 2005-03-31 | 0.53 | 0.54 | 0.01 | 1 | ||
2005-01-19 | 2004-12-31 | 0.59 | 0.58 | -0.01 | 1 | ||
2004-10-20 | 2004-09-30 | 0.54 | 0.55 | 0.01 | 1 | ||
2004-07-21 | 2004-06-30 | 0.47 | 0.47 | 0.0 | 0 | ||
2004-04-20 | 2004-03-31 | 0.51 | 0.52 | 0.01 | 1 | ||
2004-01-22 | 2003-12-31 | 0.51 | 0.53 | 0.02 | 3 | ||
2003-10-22 | 2003-09-30 | 0.44 | 0.47 | 0.03 | 6 | ||
2003-07-25 | 2003-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2003-04-22 | 2003-03-31 | 0.44 | 0.45 | 0.01 | 2 | ||
2003-01-22 | 2002-12-31 | 0.47 | 0.48 | 0.01 | 2 | ||
2002-10-16 | 2002-09-30 | 0.39 | 0.39 | 0.0 | 0 | ||
2002-07-15 | 2002-06-30 | 0.32 | 0.33 | 0.01 | 3 | ||
2002-04-17 | 2002-03-31 | 0.39 | 0.39 | 0.0 | 0 | ||
2002-01-23 | 2001-12-31 | 0.34 | 0.34 | 0.0 | 0 | ||
2001-10-17 | 2001-09-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2001-07-17 | 2001-06-30 | 0.29 | 0.3 | 0.01 | 3 | ||
2001-04-18 | 2001-03-31 | 0.31 | 0.33 | 0.02 | 6 | ||
2001-01-24 | 2000-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2000-10-24 | 2000-09-30 | 0.26 | 0.27 | 0.01 | 3 | ||
2000-07-24 | 2000-06-30 | 0.22 | 0.23 | 0.01 | 4 | ||
2000-04-18 | 2000-03-31 | 0.25 | 0.28 | 0.03 | 12 | ||
2000-01-18 | 1999-12-31 | 0.23 | 0.25 | 0.02 | 8 | ||
1999-10-19 | 1999-09-30 | 0.21 | 0.23 | 0.02 | 9 | ||
1999-07-19 | 1999-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
1999-04-15 | 1999-03-31 | 0.21 | 0.21 | 0.0 | 0 | ||
1999-01-19 | 1998-12-31 | 0.17 | 0.18 | 0.01 | 5 | ||
1998-10-13 | 1998-09-30 | 0.19 | 0.17 | -0.02 | 10 | ||
1998-07-09 | 1998-06-30 | 0.15 | 0.17 | 0.02 | 13 | ||
1998-04-14 | 1998-03-31 | 0.18 | 0.18 | 0.0 | 0 | ||
1998-01-20 | 1997-12-31 | 0.14 | 0.14 | 0.0 | 0 | ||
1997-10-14 | 1997-09-30 | 0.15 | 0.15 | 0.0 | 0 | ||
1997-07-15 | 1997-06-30 | 0.12 | 0.12 | 0.0 | 0 | ||
1997-04-15 | 1997-03-31 | 0.16 | 0.16 | 0.0 | 0 | ||
1997-01-16 | 1996-12-31 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-10-14 | 1996-09-30 | 0.13 | 0.13 | 0.0 | 0 | ||
1996-07-17 | 1996-06-30 | 0.1 | 0.1 | 0.0 | 0 | ||
1996-04-16 | 1996-03-31 | 0.13 | 0.14 | 0.01 | 7 | ||
1996-01-17 | 1995-12-31 | 0.11 | 0.11 | 0.0 | 0 | ||
1995-10-15 | 1995-09-30 | 0.11 | 0.11 | 0.0 | 0 |
Pfizer Corporate Directors
| Helen Hobbs | Independent Director | Profile | |
| Shantanu Narayen | Lead Independent Director | Profile | |
| James Smith | Independent Director | Profile | |
| Susan DesmondHellmann | Independent Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Dividend Share 1.68 | Earnings Share 1.41 | Revenue Per Share | Quarterly Revenue Growth 0.219 |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.